

# David Erritzãe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5756648/publications.pdf>

Version: 2024-02-01

51  
papers

6,263  
citations

136950

32  
h-index

182427

51  
g-index

52  
all docs

52  
docs citations

52  
times ranked

3472  
citing authors

#	ARTICLE	IF	CITATIONS
1	Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?. <i>Journal of Psychopharmacology</i> , 2022, 36, 6-11.	4.0	28
2	Psychedelics and health behaviour change. <i>Journal of Psychopharmacology</i> , 2022, 36, 12-19.	4.0	40
3	Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. <i>Psychopharmacology</i> , 2022, 239, 1425-1440.	3.1	13
4	Increased global integration in the brain after psilocybin therapy for depression. <i>Nature Medicine</i> , 2022, 28, 844-851.	30.7	175
5	Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. <i>Journal of Psychopharmacology</i> , 2021, 35, 547-555.	4.0	15
6	Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. <i>Journal of Psychopharmacology</i> , 2021, 35, 459-468.	4.0	40
7	Chronic alcohol exposure differentially modulates structural and functional properties of amygdala: A cross-sectional study. <i>Addiction Biology</i> , 2021, 26, e12980.	2.6	2
8	Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 101-118.	4.5	137
9	Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. <i>Scientific Reports</i> , 2021, 11, 1941.	3.3	76
10	Self-blinding citizen science to explore psychedelic microdosing. <i>ELife</i> , 2021, 10, .	6.0	94
11	Trial of Psilocybin versus Escitalopram for Depression. <i>New England Journal of Medicine</i> , 2021, 384, 1402-1411.	27.0	643
12	Sustained, Multifaceted Improvements in Mental Well-Being Following Psychedelic Experiences in a Prospective Opportunity Sample. <i>Frontiers in Psychiatry</i> , 2021, 12, 647909.	2.6	21
13	Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study" <i>Frontiers in Psychiatry</i> , 2021, 12, 735523.	2.6	33
14	Examining Psychedelic-Induced Changes in Social Functioning and Connectedness in a Naturalistic Online Sample Using the Five-Factor Model of Personality. <i>Frontiers in Psychology</i> , 2021, 12, 749788.	2.1	13
15	Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. <i>Frontiers in Pharmacology</i> , 2021, 12, 788155.	3.5	77
16	Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge. <i>Neuropsychopharmacology</i> , 2020, 45, 804-810.	5.4	34
17	Psychedelic Psychiatry's Brave New World. <i>Cell</i> , 2020, 181, 24-28.	28.9	162
18	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. <i>Journal of Psychopharmacology</i> , 2019, 33, 1039-1057.	4.0	121

#	ARTICLE	IF	CITATIONS
19	Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. <i>Neuropsychopharmacology</i> , 2019, 44, 1328-1334.	5.4	259
20	Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers. <i>Journal of Psychopharmacology</i> , 2019, 33, 1068-1075.	4.0	37
21	Neural correlates of the DMT experience assessed with multivariate EEG. <i>Scientific Reports</i> , 2019, 9, 16324.	3.3	144
22	Psychedelics and the essential importance of context. <i>Journal of Psychopharmacology</i> , 2018, 32, 725-731.	4.0	357
23	Psychedelics and connectedness. <i>Psychopharmacology</i> , 2018, 235, 547-550.	3.1	154
24	Are ecstasy induced serotonergic alterations overestimated for the majority of users?. <i>Journal of Psychopharmacology</i> , 2018, 32, 741-748.	4.0	14
25	DMT Models the Near-Death Experience. <i>Frontiers in Psychology</i> , 2018, 9, 1424.	2.1	122
26	Effects of psilocybin therapy on personality structure. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 368-378.	4.5	156
27	Altered Insula Connectivity under MDMA. <i>Neuropsychopharmacology</i> , 2017, 42, 2152-2162.	5.4	25
28	Concerns regarding conclusions made about LSD-treatments (received 25 October 2016). <i>History of Psychiatry</i> , 2017, 28, 257-260.	0.3	8
29	Evidence for GABA $\alpha$ receptor dysregulation in gambling disorder: correlation with impulsivity. <i>Addiction Biology</i> , 2017, 22, 1601-1609.	2.6	24
30	Neural substrates of cue reactivity and craving in gambling disorder. <i>Translational Psychiatry</i> , 2017, 7, e992-e992.	4.8	134
31	Lessons to be learned from early psychedelic therapy in Denmark. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 487-488.	1.3	10
32	Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. <i>Lancet Psychiatry</i> , 2016, 3, 619-627.	7.4	988
33	Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. <i>Neuropsychopharmacology</i> , 2016, 41, 1742-1750.	5.4	96
34	The Center for Integrated Molecular Brain Imaging (Cimbi) database. <i>NeuroImage</i> , 2016, 124, 1213-1219.	4.2	95
35	The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity. <i>Biological Psychiatry</i> , 2015, 78, 554-562.	1.3	136
36	The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 527-540.	2.1	75

#	ARTICLE	IF	CITATIONS
37	In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism. <i>Neuropsychopharmacology</i> , 2014, 39, 1703-1712.	5.4	53
38	In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1119-1128.	2.1	16
39	Amphetamine induced endogenous opioid release in the human brain detected with [11C]carfentanil PET: replication in an independent cohort. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 2069-2074.	2.1	85
40	Endogenous Opioid Release in the Human Brain Reward System Induced by Acute Amphetamine Administration. <i>Biological Psychiatry</i> , 2012, 72, 371-377.	1.3	104
41	Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases. <i>Human Psychopharmacology</i> , 2012, 27, 352-363.	1.5	31
42	Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2138-2143.	7.1	789
43	Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. <i>British Journal of Psychiatry</i> , 2012, 200, 238-244.	2.8	170
44	In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy") and Hallucinogen Users. <i>Archives of General Psychiatry</i> , 2011, 68, 562.	12.3	76
45	A Nonlinear Relationship between Cerebral Serotonin Transporter and 5-HT <sub>2A</sub> Receptor Binding: An <i>In Vivo</i> Molecular Imaging Study in Humans. <i>Journal of Neuroscience</i> , 2010, 30, 3391-3397.	3.6	52
46	Familial Risk for Mood Disorder and the Personality Risk Factor, Neuroticism, Interact in Their Association with Frontolimbic Serotonin 2A Receptor Binding. <i>Neuropsychopharmacology</i> , 2010, 35, 1129-1137.	5.4	49
47	Cerebral serotonin transporter binding is inversely related to body mass index. <i>NeuroImage</i> , 2010, 52, 284-289.	4.2	96
48	Brain serotonin 2A receptor binding: Relations to body mass index, tobacco and alcohol use. <i>NeuroImage</i> , 2009, 46, 23-30.	4.2	87
49	Cortical and Subcortical 5-HT <sub>2A</sub> Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic Patients. <i>Neuropsychopharmacology</i> , 2008, 33, 2435-2441.	5.4	64
50	Seasonal changes in brain serotonin transporter binding in short 5-HTTLPR-allele carriers but not in long-allele homozygotes. <i>Nature Precedings</i> , 2008, , .	0.1	0
51	Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. <i>Neuroimaging Clinics of North America</i> , 2003, 13, 817-832.	1.0	26